Insights, Networks, and Deal Expertise

Rahul Chaudhary is senior managing director, head of equity capital markets (ECM) at Leerink Partners, where he has successfully led his team for more than a decade. In addition to overseeing the group, he is responsible for the origination and execution of all varieties of public and private equity offerings, including IPOs, follow-ons and private investments in public equity. Since joining the company in 2009, Rahul has led more than 500 book run offerings, including more than 150 IPOs.

Formerly, he served as an integral part of Merrill Lynch’s ECM group, where he focused on origination and execution of healthcare equity and equity-linked transactions. Rahul began his career at Merrill Lynch in 2004 in the investment banking group, centered on the consumer sector, where he worked on a variety of equity, debt and M&A assignments.

Rahul earned a bachelor’s degree in finance from the University of Illinois.

Jack Bannister is a Senior Managing Director on the Equity Capital Markets team at Leerink Partners. He partners with healthcare and life sciences companies to raise capital and position them for success in the public markets.

Jack joined the Firm in 2021 from Goldman Sachs where he served as Vice President of the Healthcare Equity Capital Markets team. He began his career as an Equity Analyst with T. Rowe Price in Baltimore.

He holds a Bachelor of Arts from the University of North Carolina at Chapel Hill and an MBA from the University of Virginia Darden School of Business.

Prasanth “Burri” Rao-Kathi is a Senior Managing Director at Leerink Partners and leads the Firm’s Convertibles business.

Prior to joining the Firm in 2016, he was the Head of Equity-Linked (Convertibles) Origination in the Equity Capital Markets group at Bank of America Merrill Lynch. Burri joined the ECM group at Merrill Lynch in 1999 and worked on a number of Merrill Lynch’s landmark convertible innovations over the last 15 years including: Contingent Conversion, Contingent Payment, Bond Hedges, HiPrs, Collateralization, Simultaneous Bond and Stock Repurchases, and Prepaid Forwards in conjunction with new issues. Prior to joining Merrill Lynch, he worked in Fixed Income Swaps Marketing and Trading and Corporate Finance/ Mergers and Acquisitions at J.P. Morgan.

He is a Magna Cum Laude graduate of Georgetown University with double majors in Finance and International Business and a minor in English. He received his M.B.A. in Finance from the Wharton School of Business at the University of Pennsylvania.

Seth M. Christian is a Senior Managing Director at Leerink Partners, leading trading for our Alternative Equities business. He has over 20 years of buy-side experience and has leveraged his healthcare fund expertise to maximize trading opportunities for one of the top franchises in At-The-Market (ATM) offerings.

Prior to joining the Firm, Seth was a Managing Director and Head of Trading and Capital Markets at Broadfin Capital. He had a similar role and was on the launch team at the healthcare-focused fund, March Altus Capital. Earlier in his career, Seth held trading roles at Angel Lane Principal Strategy, Catapult/Millenium Partners and Sapphire Capital.

He earned a B.A. in Economics from Tufts University.

Peter M. Fry is a Senior Managing Director at Leerink Partners leading our Alternative Equities business. He has over 25 years of experience on both sell-side & buy-side and has built one of the market-leading franchises in At-The-Market (ATM) offerings.

Prior to joining the Firm, Peter was a Managing Director and Head of Alternative Equities at H.C. Wainwright & Co. He held similar leadership roles at Guggenheim Securities and Burrill & Company. Earlier in his career, he spent eight years as Senior Investment Officer at Kingsbridge Capital and was a Senior Healthcare Banker and Head of Public/Private Placements at Investec Inc. and RBC Capital Markets.

He earned a B.A. in Economics and Finance from Bucknell University.

Richard Mei is a Senior Managing Director at Leerink Partners focused on Equity-Linked Capital Markets.

Prior to joining the Firm in 2018, Richard was a member of the corporate finance team at Regeneron Pharmaceuticals. He has over 16 years of experience advising companies on convertible financing, equity derivatives, and liability management. Prior to Regeneron, he spent over a decade at Bank of America Merrill Lynch in various investment banking and capital markets roles.

He earned an M.B.A. from New York University and a B.S. from the University of California at Berkeley.

Patrick Morley is a Senior Managing Director in Leerink Partners’ Equity Capital Markets group, advising private and public healthcare companies on the optimal strategy and tactics to achieve their financing goals. He joined the Firm in 2011 as a member of the Healthcare Investment Banking group before transitioning to his current role.

He earned bachelor’s degrees in Industrial Engineering and Finance from Lehigh University, and is a CFA charterholder.

Dan Dubin, M.D., is the Vice Chairman, Co-President, Global Co-Head of Investment Banking and Global Co-Head of Healthcare Investment Banking at Leerink Partners and sits on the Firm’s executive committee.

For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients.  In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Barry Blake is the Global Co-Head of Investment Banking, and Global Co-Head of Healthcare Investment Banking at Leerink Partners. In this role, he co-leads the Firm’s healthcare investment banking strategy and initiatives, with a focus on Healthcare Services & Technology. With 25 years of experience, he has built extensive relationships and has proven expertise in healthcare services, medical devices and tools/diagnostics, leveraged finance, and with financial sponsors. Leading the Healthcare Services team at Leerink Partners, he has advised on numerous transactions, including the sale of LHC Group to Optum Health, a UnitedHealth Group Company, for $6B.

Barry joined the Firm in 2021 from Guggenheim Securities where he was a Senior Managing Director focused on advising healthcare services companies. While at Guggenheim he advised on many transactions including, but not limited to, the $10B sale of Envision to KKR; the $4B sale of Kindred Healthcare to a consortium comprised of TPG, Welsh Carson and Humana; the $2.4B sale of American Medical Response to KKR and the $1B sale of Almost Family to LHC Group. Prior to this, he was the Head of Global Healthcare Mergers and Acquisitions for Citigroup. While at Citigroup he worked on many transactions including, but not limited to, the $34B acquisition of Medco by Express Scripts. He also worked in the M&A and Healthcare groups at Morgan Stanley, JP Morgan and Lehman Brothers. While at JP Morgan he advised on many transactions including, but not limited to, the $4.8B acquisition of NextRx from Wellpoint by Express Scripts.

Barry earned his Bachelor of Arts in Economics from Hendrix College, and his Masters of Business Administration with high distinction from the Amos Tuck School at Dartmouth College.

He has served as a member of the Board of Trustees for each of The Hopkins School in New Haven, CT and Hendrix College in Conway, AR.

Caroline Cameron is the Chief Operating Officer of Investment Banking at Leerink Partners.

Prior to joining the Firm in 2024, Caroline was the Chief Operating Officer at Keefe, Bruyette & Woods (KBW, A Stifel Company). Prior to her time at Keefe, Bruyette & Woods, she worked in investment banking at Edgeview Partners (acquired by Piper Jaffrey), and as a research analyst at Fox-Pitt, Kelton and Macquarie Capital.

She earned a B.A. in Psychology and Economics from Hamilton College where she graduated Phi Beta Kappa.